How much has Abridge raised?

Abridge has about $450 million disclosed based on public reporting. 2019: Seed — $15 million, led/backed by UPMC Enterprises and early investors. 2022: Series A — $12.5 million, led/backed by Wittington Ventures. 2023: Series B — $30 million, led/backed by Spark Capital. 2024: Series C — $150 million, led/backed by Lightspeed Venture Partners and Redpoint Ventures. 2025: Series D — $250 million, led/backed by Elad Gil and IVP ($2.75 billion reported valuation).

Where debt, secondaries, or preferred-equity packages are included in public reporting, they are described as reported rather than converted into common-equity funding.

The disclosed investor base includes UPMC Enterprises and early investors; Wittington Ventures; Spark Capital; Lightspeed Venture Partners and Redpoint Ventures. These investors matter because they indicate whether the company is optimized for venture-scale software growth, capital-intensive deployment, clinical development, or government procurement.

For sellers, investor quality is a useful signal, but procurement timing still depends on budget ownership and integration urgency.

The latest public marker is $2.75 billion reported after 2025 Series E. Valuation movement appears tied to progress in clinical ambient ai, public customer/partner proof, and the broader investor appetite for AI-enabled category leaders.

No public source confirms profitability, so valuation should be treated as a financing-market signal rather than an operating-margin signal.

Abridge has not publicly disclosed audited profitability. IPO timing is not confirmed unless explicitly stated in company or news sources.

The practical read is that the company remains private and is using capital to extend product, hiring, regulatory, deployment, or R&D capacity.

The funding profile suggests budget exists for tools tied directly to clinical ambient ai, security, compliance, infrastructure, hiring leverage, and customer deployment. Sellers should map pitches to a funded initiative rather than a generic productivity story.

The best outreach angle is to show how a product shortens deployment time, lowers risk, or improves measurable outcomes for the teams named in the leadership and product sections.